v3.26.1
Summary of Significant Accounting Policies (Details) - USD ($)
$ in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2026
Dec. 31, 2025
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt issuance costs $ 1,400  
Accounts receivable $ 5,930 $ 4,638
Johnson & Johnson Innovative Medicine | Accounts Receivable | Credit Concentration Risk    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Concentration risk, percentage 48.00%  
Jazz: | Accounts Receivable | Credit Concentration Risk    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Concentration risk, percentage   37.00%
Performance Shares    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Performance period 3 years  
Service condition period 30 days  
Performance Shares | Minimum    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Award vesting rights, percentage 0.00%  
Absolute total shareholder return percentage 0.00%  
Relative total shareholder return percentage 0.00%  
Performance Shares | Maximum    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Award vesting rights, percentage 200.00%  
Absolute total shareholder return percentage 200.00%  
Relative total shareholder return percentage 50.00%